HPA A.I CyberSecurity Scoring
20/01/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Hamilton Process Analytics in 2026.
No incidents recorded for Hamilton Process Analytics in 2026.
No incidents recorded for Hamilton Process Analytics in 2026.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Latest updates, reports, and threat intel affecting the global network.
Below, we highlight standout companies making strides in AI for the federal government, showcasing their contributions and innovations in this critical domain.
Companies like Dominion Energy, Capital One, and Altria offer internships across software engineering, data analysis, and cybersecurity.
Top cybersecurity stocks this quarter include VeriSign Inc., Booz Allen Hamilton Corp., and CACI International Inc., shares of which have all notched double-...
Booz Allen Hamilton is most notably the most prominent management consulting partner for the US government and a leader in cybersecurity and cloud services.
Booz Allen Hamilton's Emergent Certification Program pays big money for new skills — and employees can't wait to take part. Published:.
Orebaugh, a faculty member in UVA's School of Continuing and Professional Studies, is helping train IT professionals to repel a new wave of...
Graylog is a free and open log management platform. From 6.2.0 until 6.3.12, 7.0.7, and 7.1.2, the DELETE /users/{userId}/tokens/{idOrToken} endpoint implemented by UsersResource.revokeToken() in graylog2-server/src/main/java/org/graylog2/rest/resources/users/UsersResource.java checks USERS_TOKENREMOVE permission against the attacker-controlled userId path parameter before resolving the token selected by idOrToken. An authenticated user can provide an authorized userId while accessTokenService.loadById() or accessTokenService.load() resolves a token belonging to another user, including a service account or administrator, after which accessTokenService.destroy() deletes that token without checking AccessToken.getUserName(). The issue does not expose token contents, but unauthorized deletion causes integrity impact and can disrupt access-token-based integrations. This issue is fixed in versions 6.3.12, 7.0.7, and 7.1.2.
MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb does not gate clear-text password authentication plugins on transport encryption because the AuthenticationPlugin interface has no capability for a plugin to require a secure connection. A hostile or man-in-the-middle MariaDB server can send an AuthSwitchRequest naming mysql_clear_password or dialog (PAM) over a plain-TCP unencrypted connection, and AuthenticationFlow permits ClearPasswordPluginFlow or PamPluginFlow to return the user's password as cleartext bytes on the wire. The disclosed credentials can subsequently be used to authenticate directly to the database server. This issue is fixed in version 1.4.1.
MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb encodes and decodes all character data under the assumption that the connection character set is UTF-8. A server can announce a mid-session change to character_set_client through the OK-packet session-state-tracking mechanism, including through SET NAMES executed by a stored routine or trigger, server configuration, or a hostile or man-in-the-middle server. If the new character set is not UTF-8, the driver continues to exchange UTF-8 while the server interprets the same bytes under a different encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value raises R2dbcNonTransientResourceException with SQLState 08000 and closes the connection. This issue is fixed in version 1.4.1.
MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, the connector encodes and decodes protocol text and performs client-side escaping under the assumption that the connection character set is UTF-8. The server can report a mid-session change to character_set_client through OK-packet session-state tracking, including a change caused by SET NAMES, a stored routine or trigger, server configuration, or a hostile server. If character_set_client changes to a non-UTF-8 value, the driver continues to read and write UTF-8 while the server interprets the same bytes under another encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value causes SQLException with SQLState 08000 and closes the connection. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.
MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, PAM dialog authentication can be coerced into transmitting the account password over an insecure connection. The mysql_clear_password plugin is gated behind a secure transport, but the sibling PAM handler SendPamAuthPacketFactory, named dialog by the server, does not declare that requirement and inherits the default secure-required value false; older branches implement the same affected behavior in SendPamAuthPacket. A hostile or man-in-the-middle server can send an Authentication Switch Request for dialog over plain TCP, causing the driver to return the user's password in cleartext when sslMode=DISABLE and restrictedAuth=null, which is the default configuration. Properly verified TLS and local Unix sockets are not exposed to this transport vector. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.